The Brighton Collaboration: An Overview and Preparedness for Pandemic Influenza Jane Gidudu MD, MPH Team leader April Compingbutra MPH, Paige Lewis MPH.

Slides:



Advertisements
Similar presentations
The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
Advertisements

CDCs 21 Goals. CDC Strategic Imperatives 1. Health impact focus: Align CDCs people, strategies, goals, investments & performance to maximize our impact.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Adverse Event Reporting: Getting started Lynn Bahta, R.N., B.S.N Minnesota Department of Health August 2008.
Establishing Research Priorities for Public Health Emergency Preparedness in Canada: Results of a Scoping Review and Priority- Setting Meeting Yasmin Khan,
Julianne Gee, MPH Immunization Safety Office
VACCINE SAFETY: 101 Pandemic Influenza Vaccine Safety Conference Atlanta, Georgia August 21, 2008.
© Safeguarding public health Innovation; issues for regulators, society and industry. Overview of Conference topics Alasdair Breckenridge Medicines and.
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
Comparability of Vaccine Safety Data Dr. med. Jan Bonhoeffer Coordinator, The Brighton Collaboration University Children’s Hospital Basel.
Lessons Learned in Initiating and Conducting Risk Assessments within a Risk Analysis Framework: A FDA/CFSAN Approach Robert Buchanan DHHS Food and Drug.
Welcome and Introduction John Iskander MD MPH Acting Director Immunization Safety Office.
1 VAERS Reporting During a Large Scale Vaccination Clinic in Chicago Lessons Learned Chicago Department of Public Health Immunization Program Lorraine.
CADTH Therapeutic Reviews
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
FDA/CBER Role in Smallpox Vaccine Safety Bob Ball, MD, MPH, ScM Chief, Vaccine Safety Branch Office of Biostatistics and Epidemiology CBER, FDA January.
Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Systematic Reviews and the American Academy of Pediatrics Virginia A. Moyer, MD, MPH Professor of Pediatrics Baylor College of Medicine.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
ELIZABETH WILLIAMS, MD FELLOW IN VACCINOLOGY AND VACCINE SAFETY VANDERBILT UNIVERSITY AUGUST 30 TH, 2012 Thimerosal and Vaccine Safety.
William B Munier, MD, MBA, Director Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality AHRQ Annual Conference.
Clinical Pharmacy Basma Y. Kentab MSc..
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Stakeholder Engagement and Transparency in The Effective Health Care Program Supriya Janakiraman MD MPH AHRQ.
The National Vaccine Plan Process - Update October 22, 2007 Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human Services.
by Joint Commission International (JCI)
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Pharmacovigilance Programme of India
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention February 2003.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
Smallpox Vaccine Program: Communications with the Public and Stakeholders Department of Health and Human Services Centers for Disease Control and Prevention.
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.
BMH CLINICAL GUIDELINES IN EUROPE. OUTLINE Background to the project Objectives The AGREE Instrument: validation process and results Outcomes.
Celeste F. Bové, M.A., CCC-A Senior Science Policy Analyst Office of Science Coordination & Communication Food and Drug Administration FDA Participation.
Advisory Committee for Diversity in the Digital Age.
National Vaccine Advisory Committee Report from the Chair Gus Birkhead, MD, MPH NVAC Chair February 3, 2010.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
CIFOR Council to Improve Foodborne Outbreak Response CIFOR Guidelines and CIFOR Toolkit Donald J. Sharp, MD, DTM&H Food Safety Office National Center for.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
Surgical safety is a serious public health issue About 234 million operations are done globally each year A rate of % deaths and 3-16% complications.
Surgical safety is a serious public health issue About 234 million operations are done globally each year A rate of % deaths and 3-16% complications.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
1 FDA Guidance for Industry Development and Use of Risk Minimization Action Plans Anne Trontell, M.D., M.P.H. Deputy Director CDER Office of Drug Safety.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
Immunization Safety Office Nuts and Bolts a Basic Course VACCINE SAFETY: nd National Immunization Conference Atlanta, Georgia March 17, 2008.
2010 James Fitzgerald Senior Advisor, Medicines and Health Technologies PAHO/WHO rd St Washington DC USA International Cooperation in Quality.
Comparative Effectiveness Research (CER) and Patient- Centered Outcomes Research (PCOR) Presentation Developed for the Academy of Managed Care Pharmacy.
1 |1 | Regulatory authority and Immunization programs: a joint work for patient safety Global Vaccine Safety Group Department of Essential Medicines and.
OVERVIEW OF THE WORKFORCE DEVELOPMENT DOMAIN TASK FORCE APRIL 16, 2015 Joan D. Nagel, M.D., M.P.H. Program Director, Division of Clinical Innovation National.
Comparability of Vaccine Safety Data Development of Standardized Case Definitions for Adverse Events Following Immunization Katrin S. Kohl, MD, MPH Dr.
Medical Product Safety Network (MEDSUN) an Interactive Surveillance System: Eliminating Barriers to Reporting and Creating Two-Way Communication with FDA.
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
National Immunization Conference April 19, 2010
Mary Alexander, MA, RN, CRNI®, CAE, FAAN Chief Executive Officer
CDRH 2010 Strategic Priorities
Pharmacovigilance in clinical trials
Systematic Reviews and Medical Policy Determinations
Helen Lee, European Commission
The Brighton Collaboration: A Global Vaccine Safety Effort
Pediatric Inactivated Influenza Vaccine Safety VAERS Reports for Trivalent Inactivated Influenza Vaccine (TIV) in Infants/Toddlers Ann McMahon, MD, MS.
Patient Involvement in the Development and Safe Use of
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Presentation transcript:

The Brighton Collaboration: An Overview and Preparedness for Pandemic Influenza Jane Gidudu MD, MPH Team leader April Compingbutra MPH, Paige Lewis MPH The Brighton Collaboration Team, Immunization Safety Office, Office of the Chief Science Officer CDC-Atlanta

Mission The Brighton Collaboration is an international voluntary collaboration with a mission to facilitate the development, evaluation, and dissemination of high- quality information about the safety of human vaccines

Global Standardization Vacines are used worldwide Standardization of Adverse Events Following Immunization (AEFI) Facilitates comparability and communication of safety data Enhancement of trust in current immunization programs

Background – The Need Safety cannot be measured directly, only inferred from the relative absence of AEFIs Assessing safety requires standardized terminology of AEFI Lack of a standard “vocabulary” (i.e., case definitions & guidelines) for AEFI has hindered comparability of vaccine safety data

A global collaboration to address this “missed opportunity” Development of standardized case definitions and guidelines Case definitions categorized by levels of evidence  Clinical trials vs. post marketing surveillance  Developed vs. developing countries Background – The Solution

Network of Participants (N=1819) June countries with > 2 participants with 1 participant 69 countries

Brighton Process Select or prioritize an adverse event to be defined Initiate a 6-step process  Review literature for available evidence  Form working groups  Develop draft definitions and guidelines  Review and evaluate draft  Review and receive endorsement from the CIOMS and WHO vaccine pharmaco-vigilance committee  Finalize and disseminate documents

Highlighted Achievements “Success is the progressive realization of a predetermined worthwhile goal” Paul J Meyer

Case Definitions Anaphylaxis Aseptic meningitis Encephalitis, myelitis, and ADEM Fever Fatigue Hypotonic-hyporesponsive episode Intussusception Local reactions  abscess  cellulitis  nodule  induration  swelling Persistent crying Rash Seizure Thrombocytopenia Unexplained sudden infant death including SIDS Vaccinia  eczema vaccinatum  inadvertent inoculation  generalized vaccinia  progressive vaccinia  robust take

Case Definition Format (5 Categories ) Level 1 of diagnostic certainty [most specific least sensitive] Level 2 of diagnostic certainty [intermediate] Level 3 of diagnostic certainty [least specific, most sensitive] 2 Additional categories for data analysis  Reported [AEFI] with insufficient evidence  Not a case of [AEFI]

Example: Intussusception Level 1  Surgical criteria AND/OR  Radiological criteria AND/OR  Autopsy criteria Level 2  Clinical criteria  2 Major* OR I major & 3 minor ¥ criteria Level 3  Clinical criteria  >4 minor ¥ criteria * Major criteria include: evidence of intestinal obstruction, features if intestinal invagination, evidence of intestinal vascular compromise or venous congestion ¥ Minor criteria include: predisposing factors such as abdominal pain, vomiting lethargy, pallor, hypovolemic shock, plain abdominal radiograph

Applicability in Surveillance Systems Check list for active follow-up Validation of data  Report & signal generation Standardized safety assessment  Comparability with other studies Improved value of surveillance data

Global Recognition and Recommendation World Health Organization (WHO) US Centers for Disease Control and Prevention (CDC) European Centers for Disease Control and Prevention (ECDC) US Food and Drug Administration (FDA) Council for International Organization of Medical Sciences (CIOMS) European Agency for the Evaluation of Medicinal Product (EMEA) American Academy of Pediatrics (AAP) Council for International Medical Sciences (CIOMS)

Evaluating Brighton case definitions in the VAERS system beginning with adverse events [anaphylaxis, bells palsy] anticipated to occur in mass influenza vaccination setting. Validating these case definitions for incorporation into case assessment report form for monitoring adverse events following immunization. We strive to establish a system that can flag confirmed cases of adverse events in our VAERS system for evidence based decisions Pandemic Activities

Summary The Brighton Collaboration is a growing global network of experts and scientists concerned with vaccine safety. The common goal is to facilitate data comparability across studies in different settings. We have a voluntary platform for over 1800 participants in over 90 countries. The collaboration consists of various disciplines (academia, patient care, industry, regulatory and public health organizations).

Summary (continued) A total of 22 case definitions have been published in Vaccine. We use a systematic and transparent, scientific process. Our team is currently focusing on key pandemic preparedness activities such as evaluating adverse events anticipated in pandemic influenza We strive to establish a system that can flag confirmed cases meeting our validated criteria Case definitions can be accessed freely online at: wnload.html

Many Thanks!